Literature DB >> 15210551

Clinical course of recurrent respiratory papillomatosis in Danish children.

Michael J Silverberg1, Poul Thorsen, Henning Lindeberg, Linda Ahdieh-Grant, Keerti V Shah.   

Abstract

OBJECTIVE: To evaluate the clinical course of juvenile-onset recurrent respiratory papillomatosis (RP) with respect to age, disease duration, and maternal condylomas.
DESIGN: Inception cohort study.
SETTING: All ear, nose, and throat departments in public Danish hospitals. PATIENTS: Fifty-seven Danish children diagnosed with RP and born between 1974 and 1993 were observed for an average of 14 years after diagnosis. MAIN OUTCOME MEASURE: Removal of respiratory papillomas by knife biopsy, laser surgery, or cryotherapy.
RESULTS: Children younger than 5 years diagnosed with RP underwent an average of 4.1 surgeries in the first year of disease, the highest rate among all our patients. The overall surgery rate decreased over time after initial diagnosis but remained significantly higher for children with a younger age of onset for the first 4 years of disease (P <.001) and for children with a maternal history of condylomas in pregnancy for years 4 to 10 of the disease (P <.001). We also observed an independent and statistically significant (P <.001) decreasing surgery rate with increasing age and time from initial diagnosis. The trend for children with recurrent disease was a decreasing rate of surgical procedures (28 of 42 patients with recurrent disease); however, a third of patients (14/42) demonstrated a constant or increasing rate of surgical procedures over time.
CONCLUSIONS: The clinical course of RP is characterized by a high frequency of surgeries soon after diagnosis that diminishes over time and with increasing age. Additional studies are warranted to identify factors associated with cases that do not conform to the usual disease course.

Entities:  

Mesh:

Year:  2004        PMID: 15210551     DOI: 10.1001/archotol.130.6.711

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  14 in total

1.  Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients.

Authors:  R E A Tjon Pian Gi; T Ilmarinen; E R van den Heuvel; L M Aaltonen; J Andersen; J W Brunings; M Chirila; A Dietz; F Ferran Vilà; G Friedrich; H H W de Gier; W Golusinski; M Graupp; A Hantzakos; R Horcasitas; J Jackowska; J C Koelmel; G Lawson; F Lindner; M Remacle; C Sittel; V Weichbold; M Wierzbicka; F G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-02-03       Impact factor: 2.503

Review 2.  Recurrent respiratory papillomatosis.

Authors:  Naren N Venkatesan; Harold S Pine; Michael P Underbrink
Journal:  Otolaryngol Clin North Am       Date:  2012-06       Impact factor: 3.346

Review 3.  Position paper--HPV and the primary prevention of cancer; improving vaccine uptake by paediatricians.

Authors:  José Ramet; Diego van Esso; Zsofia Meszner
Journal:  Eur J Pediatr       Date:  2010-08-05       Impact factor: 3.860

Review 4.  Recurrent respiratory papillomatosis: current and future perspectives.

Authors:  Marco Carifi; Domenico Napolitano; Morando Morandi; Danilo Dall'Olio
Journal:  Ther Clin Risk Manag       Date:  2015-05-05       Impact factor: 2.423

5.  Epidermal growth factor receptor inhibitor therapy for recurrent respiratory papillomatosis.

Authors:  Matthew M Moldan; Bruce C Bostrom; Robert J Tibesar; Timothy A Lander; James D Sidman
Journal:  F1000Res       Date:  2013-10-03

Review 6.  An update on oral human papillomavirus infection.

Authors:  Ankit H Bharti; Kiran Chotaliya; Y S Marfatia
Journal:  Indian J Sex Transm Dis AIDS       Date:  2013-07

7.  Risk factors for aggressive recurrent respiratory papillomatosis in adults and juveniles.

Authors:  Turid Omland; Harriet Akre; Kathrine A Lie; Peter Jebsen; Leiv Sandvik; Kjell Brøndbo
Journal:  PLoS One       Date:  2014-11-24       Impact factor: 3.240

8.  Juvenile-Onset Recurrent Respiratory Papillomatosis in the United States, Epidemiology and HPV Types-2015-2020.

Authors:  Raiza Amiling; Elissa Meites; Troy D Querec; Laura Stone; Vidisha Singh; Elizabeth R Unger; Craig S Derkay; Lauri E Markowitz
Journal:  J Pediatric Infect Dis Soc       Date:  2021-08-17       Impact factor: 5.235

9.  Age of child, more than HPV type, is associated with clinical course in recurrent respiratory papillomatosis.

Authors:  Farrel J Buchinsky; Joseph Donfack; Craig S Derkay; Sukgi S Choi; Stephen F Conley; Charles M Myer; John E McClay; Paolo Campisi; Brian J Wiatrak; Steven E Sobol; John M Schweinfurth; Domingos H Tsuji; Fen Z Hu; Howard E Rockette; Garth D Ehrlich; J Christopher Post
Journal:  PLoS One       Date:  2008-05-28       Impact factor: 3.240

10.  A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France.

Authors:  Xavier Bresse; Marjorie Adam; Nathalie Largeron; Stephane Roze; Rémi Marty
Journal:  Hum Vaccin Immunother       Date:  2013-04-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.